S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
Log in

Neurometrix Stock Price, Forecast & Analysis (NASDAQ:NURO)

$0.28
-0.01 (-3.45 %)
(As of 11/12/2019 04:00 PM ET)
Today's Range
$0.26
Now: $0.28
$0.30
50-Day Range
$0.26
MA: $0.30
$0.37
52-Week Range
$0.25
Now: $0.28
$1.38
Volume71,800 shs
Average Volume140,301 shs
Market Capitalization$2.74 million
P/E RatioN/A
Dividend YieldN/A
Beta0.52
NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NURO
CUSIPN/A
Phone781-890-9989

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.09 million
Cash Flow$0.02 per share
Book Value$0.79 per share

Profitability

Net Income$20,000.00

Miscellaneous

Employees42
Market Cap$2.74 million
Next Earnings Date1/23/2020 (Estimated)
OptionableNot Optionable

Receive NURO News and Ratings via Email

Sign-up to receive the latest news and ratings for NURO and its competitors with MarketBeat's FREE daily newsletter.


Neurometrix (NASDAQ:NURO) Frequently Asked Questions

What is Neurometrix's stock symbol?

Neurometrix trades on the NASDAQ under the ticker symbol "NURO."

When did Neurometrix's stock split? How did Neurometrix's stock split work?

Shares of Neurometrix reverse split on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of Neurometrix stock prior to the reverse split would have 13 shares after the split.

How were Neurometrix's earnings last quarter?

Neurometrix Inc (NASDAQ:NURO) released its earnings results on Thursday, October, 17th. The medical device company reported ($0.14) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.01. The medical device company had revenue of $2.09 million for the quarter, compared to analyst estimates of $3.94 million. Neurometrix had a negative net margin of 48.86% and a negative return on equity of 65.19%. View Neurometrix's Earnings History.

When is Neurometrix's next earnings date?

Neurometrix is scheduled to release their next quarterly earnings announcement on Thursday, January 23rd 2020. View Earnings Estimates for Neurometrix.

What price target have analysts set for NURO?

1 equities research analysts have issued 1 year price objectives for Neurometrix's shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Neurometrix's stock price to reach $5.00 in the next year. This suggests a possible upside of 1,685.7% from the stock's current price. View Analyst Price Targets for Neurometrix.

What is the consensus analysts' recommendation for Neurometrix?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurometrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neurometrix.

Has Neurometrix been receiving favorable news coverage?

News coverage about NURO stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Neurometrix earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the medical device company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Neurometrix.

Are investors shorting Neurometrix?

Neurometrix saw a decrease in short interest in October. As of October 15th, there was short interest totalling 118,100 shares, a decrease of 8.9% from the September 15th total of 129,600 shares. Based on an average trading volume of 114,100 shares, the short-interest ratio is currently 1.0 days. Approximately 1.2% of the shares of the company are sold short. View Neurometrix's Current Options Chain.

Who are some of Neurometrix's key competitors?

What other stocks do shareholders of Neurometrix own?

Who are Neurometrix's key executives?

Neurometrix's management team includes the folowing people:
  • Dr. Shai N. Gozani, Founder, Chairman, CEO, Pres & Sec. (Age 54)
  • Mr. Thomas T. Higgins, Sr. VP, CFO & Treasurer (Age 67)
  • Mr. Francis X. McGillin, Sr. VP & Chief Commercial Officer (Age 58)
  • Mr. Michael J. MacDonald, Sr. VP of Commercial Operations & GM of Diagnostics
  • Dr. Xuan Kong Ph.D., Chief Data Scientist

How do I buy shares of Neurometrix?

Shares of NURO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurometrix's stock price today?

One share of NURO stock can currently be purchased for approximately $0.28.

How big of a company is Neurometrix?

Neurometrix has a market capitalization of $2.74 million and generates $16.09 million in revenue each year. Neurometrix employs 42 workers across the globe.View Additional Information About Neurometrix.

What is Neurometrix's official website?

The official website for Neurometrix is http://www.neurometrix.com/.

How can I contact Neurometrix?

Neurometrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The medical device company can be reached via phone at 781-890-9989 or via email at [email protected]


MarketBeat Community Rating for Neurometrix (NASDAQ NURO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Neurometrix and other stocks. Vote "Outperform" if you believe NURO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NURO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Featured Article: Dead Cat Bounce

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel